HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hnatowich, D. J. Articles by Doherty, P. W. Search for Related Content PubMed PubMed Citation Articles by Hnatowich, D. J. Articles by Doherty, P. W.

DTPA-Coupled Antibodies Labeled with Yttrium-90

Department of Nuclear Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts

Correspondence: For reprints contact: D. J. Hnatowich, PhD, Dept. of Nuclear Medicine, University of Massachusetts Med. Ctr., Worcester, MA 01605.

ABSTRACT

Yttrium-90 has been described as one of the best radionuclides for tumor therapy when chelated to tumor-associated antibodies. This evaluation is based on the superior properties of this radionuclide (suitable half-life, pure beta-ray emitter of intermediate energy, stable daughter, and suitable chemical properties) and because it is available as a radionuclide generator product by decay of its 28-yr parent ⁹⁰Sr. We have determined that ⁹⁰Y obtained from one such generator is suitable for labeling antibodies coupled with DTPA. Furthermore, we have shown that the dissociation rate of [⁹⁰Y]DTPA-lgG in serum at 37°C is similar to that of [¹¹¹ln]DTPA-lgG at about 89%/day. Biodistribution studies of ¹¹¹ln- and ⁹⁰Y-labeled to DTPA-coupled lgG show that the labels distribute nearly identically at 1 hr postadministration, although differences in distribution are apparent at 24 hr. It is possible that these differences reflect the redistribution of the labels following catabolism at the site of localization.

This article has been cited by other articles:

				M. D. Winthrop, S. J. DeNardo, H. Albrecht, G. R. Mirick, L. A. Kroger, K. R. Lamborn, C. Venclovas, M. E. Colvin, P. A. Burke, and G. L. DeNardo Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy Clin. Cancer Res., September 1, 2003; 9(10): 3845S - 3853. [Abstract] [Full Text] [PDF]